
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is tackling the global issue of viral infections by utilizing their expertise in monoclonal antibody (mAb) therapies. Their lead product, PEMGARDA, has already received FDA authorization for pre-exposure prevention of COVID-19 in immunocompromised individuals, and they have a strong pipeline of next-generation antibodies targeting various viral diseases. The company also has a strong potential for commercial success, with a promising development and regulatory pathway for their products. With enrollment complete for their Phase 3 DECLARATION study, and sufficient events recorded for a positive result, the focus now shifts to VYD2311 and its expected positive results, which have the potential to propel the stock forward.
Bears say
Invivyd is heavily focused on monoclonal antibody therapies for the treatment and prevention of viral infectious diseases, with its lead product receiving FDA approval for pre-exposure prevention of COVID-19 in certain immunocompromised individuals. However, the current upward trend in COVID-19 transmission and hospitalizations, as well as the company's reliance on a single product for commercial success, raise concerns about its financial performance in the short-term. This, combined with potential risks in clinical readouts and regulatory uncertainties, may make Invivyd's stock a risky investment option.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares